UK markets closed

MorphoSys AG (MOR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.4600-0.1700 (-3.67%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 610.57M
Enterprise value 222.04M
Trailing P/E N/A
Forward P/E 322.58
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.17
Price/book (mrq)N/A
Enterprise value/revenue 1.14
Enterprise value/EBITDA -0.35

Trading information

Stock price history

Beta (5Y monthly) 0.97
52-week change 3-63.95%
S&P500 52-week change 3-16.88%
52-week high 312.5300
52-week low 34.0700
50-day moving average 35.1571
200-day moving average 36.3333

Share statistics

Avg vol (3-month) 339.13k
Avg vol (10-day) 361.35k
Shares outstanding 5136.61M
Implied shares outstanding 6N/A
Float 8131.19M
% held by insiders 10.00%
% held by institutions 12.08%
Shares short (30 Aug 2022) 4169.33k
Short ratio (30 Aug 2022) 43.95
Short % of float (30 Aug 2022) 4N/A
Short % of shares outstanding (30 Aug 2022) 40.12%
Shares short (prior month 28 Jul 2022) 4111.68k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin 0.00%
Operating margin (ttm)-141.93%

Management effectiveness

Return on assets (ttm)-8.47%
Return on equity (ttm)-296.68%

Income statement

Revenue (ttm)195.1M
Revenue per share (ttm)1.43
Quarterly revenue growth (yoy)55.50%
Gross profit (ttm)147.42M
EBITDA -270.09M
Net income avi to common (ttm)-851.39M
Diluted EPS (ttm)-4.6112
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)726.83M
Total cash per share (mrq)5.32
Total debt (mrq)331.94M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.98
Book value per share (mrq)-0.20

Cash flow statement

Operating cash flow (ttm)-587.87M
Levered free cash flow (ttm)-170.45M